Skip to main
MLTX
MLTX logo

MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target

MoonLake Immunotherapeutics (MLTX) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 53%
Buy 40%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

MoonLake Immunotherapeutics is positioned favorably due to its focus on SLK, a tri-specific IL-17A and IL-17F inhibiting Nanobody, which has demonstrated robust efficacy in clinical trials and shows potential for disease modification in inflammatory skin and joint disorders. The company is anticipating pivotal data this year, indicating a significant opportunity for growth, particularly in hidradenitis suppurativa (HS), a condition with considerable unmet medical needs and increasing market awareness. Additionally, with sales of comparable therapies like Cosentyx exceeding $970 million, SLK's positive clinical outcomes and potential expansion into other inflammatory indications further support a compelling investment thesis.

Bears say

MoonLake Immunotherapeutics faces significant risks that could lead to a negative outlook on its stock, primarily due to potential safety concerns and efficacy issues related to its drug SLK, which could hinder the progression of clinical trials and the probability of success. The company's recent net loss of $44.2 million in Q4 2024 underscores its financial challenges, while regulatory hurdles and the need for further safety data could introduce delays that affect revenue generation prospects. Furthermore, competitive disadvantages, such as lack of differentiation from existing treatments and the risks associated with being a second-to-market option, create additional uncertainty around the company's future performance.

MoonLake Immunotherapeutics (MLTX) has been analyzed by 15 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 40% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MoonLake Immunotherapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MoonLake Immunotherapeutics (MLTX) Forecast

Analysts have given MoonLake Immunotherapeutics (MLTX) a Buy based on their latest research and market trends.

According to 15 analysts, MoonLake Immunotherapeutics (MLTX) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $64.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $64.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MoonLake Immunotherapeutics (MLTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.